Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksByotrol Regulatory News (BYOT)

Share Price Information for Byotrol (BYOT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.10
Bid: 0.05
Ask: 0.15
Change: -0.025 (-20.00%)
Spread: 0.10 (200.00%)
Open: 0.125
High: 0.125
Low: 0.10
Prev. Close: 0.125
BYOT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licence and Product Supply Agreement with Tristel

23 Mar 2020 07:00

RNS Number : 1185H
Byotrol PLC
23 March 2020
 

 

 

 

 

Byotrol plc ("Byotrol" or the "Company")

Know-How Licence and Product Supply Agreement with Tristel plc

 

 

Byotrol is pleased to announce a new collaboration ("the Agreement") with fellow infection prevention and control specialists Tristel plc.

 

The Agreement relates to three specific technologies

 

1. A concentrated surface disinfectant initially targeted for use in hospitals, dispensed from Tristel's proprietary Cache system of innovative packaging solutions; and

2. A concentrated surface disinfectant with long-lasting (8 hour) anti-microbial efficacy also to be dispensed from Tristel's proprietary Cache system. This product is a concentrate version of ACTIZONE, a Solvay technology developed in conjunction with Byotrol; and

3. A unique surface disinfectant combining Tristel's proprietary sporicidal chemistry, with Byotrol's long-lasting anti-microbial technology, also based on the ACTIZONE technology platform. The combined product will speedily eliminate spores on application, and will then remain active against microbes for an 8-hour period after application. Tristel will incorporate the jointly developed formulation in several packaging formats under the family name "Tristel8". 

The Agreement has a duration of 10 years and will be exclusive in hospitals in the UK and Ireland and non-exclusive elsewhere. Under the terms of the Agreement, Tristel will pay to Byotrol a combination of product supply payments, royalties and fees, based on success but with meaningful minimum guarantee payments to Byotrol each year.

 

 

David Traynor, Chief Executive of Byotrol, said:

 

"We are really pleased to be working with Tristel in this way and are particularly pleased that our chemistries now work in combination, with genuinely unique new product claims at a key time in infection control. This agreement now brings our products to many more customers in healthcare and beyond, and in formats that we could not do on our own"

 

 

Enquiries:

 

Byotrol plc

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer 01925 742 000

 

finnCap

Geoff Nash/ Richard Chambers - Corporate Finance 020 7220 0500

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading infection prevention and control technology company, operating globally in the Food, Industrial, Healthcare and Consumer sectors, providing low toxicity products with a broad-based and long-lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, mycobacteria and algae.

 

Powerful, long-lasting and gentle, Byotrol's products can be used stand-alone or as ingredients within existing products, where Byotrol can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company develops technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to www.byotrol.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRJTMMTMTMTTJM
Date   Source Headline
1st Aug 20187:00 amRNSNotice of Results
17th May 20187:00 amRNSFirst US Retail Trial with Target
10th May 20184:32 pmRNSHolding(s) in Company
10th May 20187:00 amRNSState approval in US
23rd Apr 20183:07 pmRNSHolding(s) in Company
11th Apr 20187:00 amRNSTrading Statement
26th Feb 20183:10 pmRNSHolding(s) in Company
18th Jan 20187:00 amRNSDirector Dealing
14th Dec 20177:01 amRNSKey US Hire & Grant of Options
14th Dec 20177:00 amRNSInterim Results
7th Dec 20177:00 amRNSNotice of Results
10th Nov 20177:00 amRNSGrant of Options & Director/PDMR Shareholdings
28th Sep 201711:49 amRNSResult of AGM
6th Sep 201712:48 pmRNSHolding(s) in Company
6th Sep 201711:37 amRNSForm 8.3 - Byotrol Plc
6th Sep 201711:31 amRNSHolding(s) in Company
5th Sep 20174:37 pmRNSHolding(s) in Company
5th Sep 20174:36 pmRNSHolding(s) in Company
5th Sep 20174:35 pmRNSHolding(s) in Company
4th Sep 201711:57 amRNSResult of General Meeting
31st Aug 20177:00 amRNSResult of Open Offer
30th Aug 20179:24 amRNSPosting of Annual Report and Notice of AGM
29th Aug 20171:19 pmRNSConversion of Loan Notes and Issue of Equity
17th Aug 20172:31 pmRNSHolding(s) in Company
8th Aug 20174:47 pmRNSPlacing & Open Offer Timetable
7th Aug 20179:44 amRNSHolding(s) in Company
3rd Aug 201712:00 pmRNSResult of Proposed Fundraising
3rd Aug 20177:01 amRNSProposed Fundraising
3rd Aug 20177:00 amRNSFinal Results
13th Jun 20177:00 amRNSEPA Approval
13th Mar 20177:00 amRNSAcquisition
6th Feb 20177:00 amRNSDirector Dealing
1st Feb 20177:00 amRNSBoard changes and issue of options
13th Dec 20167:00 amRNSInterim Results
7th Dec 201612:29 pmRNSNotice of Interim Results
14th Oct 20167:00 amRNSGrant of Options and Director Shareholdings
12th Oct 20167:00 amRNSTransfer of Convertible Loan Notes
30th Sep 20163:16 pmRNSResult of Noteholders Meeting
22nd Sep 20164:51 pmRNSResult of AGM
9th Sep 20167:00 amRNSProposed Revision to Loan Notes
18th Aug 20167:00 amRNSFinal Results
8th Jul 20167:00 amRNSTrading Update and Notice of AGM
25th Feb 20167:00 amRNSTrading Statement
19th Feb 20163:34 pmRNSDirector/PDMR Shareholding
3rd Dec 20158:00 amRNSGrant of Options
3rd Dec 20157:00 amRNSInterim Results
9th Sep 201512:06 pmRNSHolding(s) in Company
8th Sep 20154:05 pmRNSResult of AGM and Completion of Placing
24th Aug 20151:57 pmRNSHolding(s) in Company
20th Aug 20151:00 pmRNSPlacing and Subscription to raise £1.4 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.